#1 Clinical Trials Search in Europe
EU – Europe
AT – Austria
HR – Croatia
CZ – Czech Republic
DK – Denmark
EE – Estonia
FI – Finland
FR – France
DE – Germany
IS – Iceland
IT – Italy
LV – Latvia
LT – Lithuania
NL – Netherlands
NO – Norway
PL – Poland
PT – Portugal
RO – Romania
SK – Slovakia
SI – Slovenia
ES – Spain
SE – Sweden
  • Find a Clinical Trial

    Search Trials by Disease

    Non-small cell lung cancer Breast cancer Plasma cell myeloma Neoplasm Acute myeloid leukaemia Neoplasm malignant Colitis ulcerative Obesity Colorectal cancer metastatic Prostate cancer Crohn's disease Ovarian cancer Colorectal cancer Hepatocellular carcinoma Dermatitis atopic Dementia Alzheimer's type Asthma Type 2 diabetes mellitus Breast cancer metastatic Non-small cell lung cancer metastatic More trials…
  • Rare Diseases Treatments

    Search Trials by Disease

    Chronic cutaneous lupus erythematosus PIK3CA-activated mutation Vulval cancer recurrent Pleural mesothelioma malignant Thermal burn Germ cell cancer Marfan's syndrome Acute myeloid leukaemia (in remission) Progressive supranuclear palsy Synovial sarcoma recurrent Von Hippel-Lindau disease Non-small cell lung cancer Lung adenocarcinoma Endometrial cancer recurrent Chronic graft versus host disease More trials…

    Learn about Rare Diseases

    Hereditary angioedema – Trials in Disease Lymphangiosarcoma – Trials in Disease Hereditary angioedema – Treatment Alagille syndrome – Basic Information Ewing’s sarcoma – Treatment Glycogen storage disease type II Mucopolysaccharidosis II – Basic Information Rhabdoid tumour – Treatment Rett syndrome – Basic Information Piriformis syndrome – Treatment More diseases
  • Vaccine Clinical Trials
  • Pediatric Clinical Trials
  • Resources for Patients

    Browse Innovative Treatments

    Sertindole Mps-214 Cpk850 Cx-044933 Tamsulosin Hydrochloride Istaroxime Tominersen Eletriptan Solrikitug 64Cu-Dota-Ae105 Elafibranor Heparin Calcium Botulinum Toxin Type A Alizapride NAVENIBART Methylphenidate Hydrochloride Mirodenafil Dihydrochloride Isis 696844 IMB 101 Melatonin More therapies…

    Learn about Your Condition

    Asthma Systemic mastocytosis Renal cancer recurrent Peritoneal cancer index Rectal cancer recurrent Epicondylitis Glanzmann's disease Ischaemic stroke Colorectal adenocarcinoma Acne Psychogenic seizure Influenza Juvenile absence epilepsy Scoliosis Kaposi's sarcoma More diseases
  • Healthy Volunteers
  • Patient Guide
  • Our Partners
  • About Us
  • Contact us
  • Region
    🇪🇺 Europe
    🇦🇹 Austria
    🇭🇷 Croatia
    🇨🇿 Czech Republic
    🇩🇰 Denmark
    🇪🇪 Estonia
    🇫🇮 Finland
    🇫🇷 France
    🇩🇪 Germany
    🇮🇸 Iceland
    🇮🇹 Italy
    🇱🇻 Latvia
    🇱🇹 Lithuania
    🇳🇱 Netherlands
    🇳🇴 Norway
    🇵🇱 Poland
    🇵🇹 Portugal
    🇷🇴 Romania
    🇸🇰 Slovakia
    🇸🇮 Slovenia
    🇪🇸 Spain
    🇸🇪 Sweden
  1. Clinicaltrials.eu/
  2. Istituto Oncologico Veneto

Istituto Oncologico Veneto

Via Gattamelata 64, Padua, 35128, Italy

Want to learn more about this study or check if you can participate? Contact us.

  • Study on TAR-200 and Cetrelimab for Patients with High-Risk Non-Muscle Invasive Bladder Cancer Who Have Not Received BCG Treatment

    Not recruiting

    3 1 1 1
    Investigated Drugs:
    • Cetrelimab
    • Gemcitabine Hydrochloride
    Belgium Czechia France Germany Italy The Netherlands +3

  • Study Comparing Nivolumab, Nivolumab with Ipilimumab, or Chemotherapy for Patients with Metastatic Colorectal Cancer with High Microsatellite Instability

    Not recruiting

    3 1 1 1
    Investigated Diseases:
    • Colorectal cancer metastatic
    Investigated Drugs:
    • Bevacizumab
    • Disodium Folinate
    • Fluorouracil
    Austria Belgium Czechia Denmark France Germany +6

  • Study Comparing Pralsetinib and Standard Drug Combination for Patients with Advanced RET Fusion-Positive Non-Small Cell Lung Cancer

    Not recruiting

    3 1 1 1
    Investigated Diseases:
    • Lung neoplasm malignant
    • Non-small cell lung cancer
    Investigated Drugs:
    • Carboplatin
    • Cisplatin
    • Gemcitabine
    Belgium France Germany Ireland Italy The Netherlands +4

  • Study Comparing Nivolumab and Cabozantinib with Sunitinib for Patients with Untreated Advanced Kidney Cancer

    Not recruiting

    3 1 1 1
    Investigated Diseases:
    • Metastatic renal cell carcinoma
    Investigated Drugs:
    • Cabozantinib
    • Ipilimumab
    • Nivolumab
    Czechia Germany Greece Italy Poland Romania +1

  • Study for Patients with Metastatic Colorectal Cancer with BRAF V600E Mutation Using Encorafenib, Cetuximab, and Chemotherapy Combination

    Not recruiting

    3 1 1 1
    Investigated Diseases:
    • Colorectal cancer
    Investigated Drugs:
    • Bevacizumab
    • Calcium Folinate
    • Capecitabine
    Belgium Bulgaria Czechia Denmark Finland Germany +7

  • Study Comparing Relatlimab and Nivolumab Combination vs. Nivolumab Alone for Patients with Advanced Melanoma

    Not recruiting

    4 1 1 1
    Investigated Drugs:
    • Nivolumab
    • Relatlimab
    Austria Belgium Denmark Finland France Germany +7

  • Study of Nivolumab, Relatlimab and Bevacizumab combination for patients with untreated advanced or metastatic liver cancer (hepatocellular carcinoma)

    Not recruiting

    1 1 1
    Investigated Drugs:
    • Bevacizumab
    • Nivolumab
    • Relatlimab
    France Germany Italy Poland Spain

  • Study of IO102-IO103 and Pembrolizumab for Patients with Advanced Melanoma

    Not recruiting

    3 1 1 1
    Investigated Diseases:
    • Metastatic malignant melanoma
    Investigated Drugs:
    • Io102 Hydrochloride
    • Pembrolizumab
    Belgium Czechia Denmark France Germany Hungary +4

  • Study of Pembrolizumab with Chemotherapy for Patients with Advanced Gastric or Gastroesophageal Junction Cancer

    Not recruiting

    3 1 1
    Investigated Diseases:
    • Adenocarcinoma gastric
    • Oesophageal adenocarcinoma
    Investigated Drugs:
    • Capecitabine
    • Cisplatin
    • Fluorouracil
    Czechia Denmark France Germany Ireland Italy +2

  • Study on the Safety and Tolerance of BI 907828 in Patients with Advanced Dedifferentiated Liposarcoma

    Not recruiting

    3 1 1
    Investigated Diseases:
    • Dedifferentiated liposarcoma
    Investigated Drugs:
    • (3S,3’S,3A’s,10A’s)-6-Chloro-3′-(3-Chloro-2-Fluorophenyl)-1′-(Cyclopropylmethyl)-6′-Methyl-2-Oxo-1,2,3′,3A’,10′,10A’-Hexahydro-1’H-Spiro[Indole-3,2′-Pyrrolo[2′,3′:4,5]Pyrrolo[1,2-B]Indazole]-7′-Carboxylic Acid
    Belgium Italy
Previous Page
1 … 31 32 33 34 35 … 42
Next Page

European Clinical Trials Information Network

The European Clinical Trials Information Network is transforming access to clinical trial information for patients across Europe. By overcoming language barriers, our platform allows everyone, regardless of their native language, to easily find relevant and comprehensible clinical trial data. This innovative service connects patients to cutting-edge treatments, creating a unified European community where health and progress transcend borders.

This service is not affiliated with the European Commission, the EMA, or the official CTIS system. Most information comes from publicly available international clinical-trial registries, supplemented by data from academic centres, national regulators, and commercial sponsors. We aim to keep all content accurate and up to date.

Explore the full ecosystem of clinical research in Europe.

The information provided on this website is mainly derived from international public clinical trial databases (CTIS.eu). In addition, we are including supplementary sources, such as information provided by academic centers and national regulators, as well as information supplied by commercial sponsors (pharmaceutical companies and contract research organizations). We try to ensure that the information provided is accurate and up to date.

Certain content and visual elements on this website have been generated or enhanced using artificial intelligence (AI).

The website is published by:
CTIN POLAND sp. z o.o.
with its registered office in Warsaw,
ul. rtm. Witolda Pileckiego 67/109,
02-781 Warsaw, Poland,
entered in the Register of Entrepreneurs of the National Court Register under KRS number 0001111334,
REGON: 528919042, NIP (Tax ID): 9512598637
Contact us

© 2026 CTIN Poland

Privacy Policy

Terms and Conditions

Contact

For Sites and Sponsors

Clinical Trial Locations

We use cookies

The website uses cookies to ensure the proper functioning of the site and to analyze internet traffic. Some cookies are essential for using the service and do not require consent. You can accept all cookies or use only the essential ones. Data is processed in accordance with our Privacy Policy. You have the right to withdraw your consent, access, rectify, delete, or limit the processing of your data at any time.
Numer nieprawidłowy!
Numer nieprawidłowy!